Search

Search Results

• IMMUNOTHERAPY FOR EPSTEIN-BARR VIRUS-RELATED LYMPHOMAS

  Alana Kennedy-Nasser, Catherine Bollard, Helen Heslop

  e2009010

  2009-11-13

  https://doi.org/10.4084/mjhid.2009.010

  1173

  PDF: 604

  HTML: 6798

• MODERN IMMUNOTHERAPY OF ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS

  Elena Maino, Anna Maria Scattolin, Piera Viero, Rosaria Sancetta, Anna Pascarella, Michele Vespignani, Renato Bassan

  e2015001

  2015-01-01

  https://doi.org/10.4084/mjhid.2015.001

  2301

  PDF: 1327

  HTML: 17082

  Bassan Fig.1: 144

  Bassan Fig.2: 156

  Bassan Fig.4: 142

  Fig.3: 187

• CUPROPTOSIS: A REVIEW ON MECHANISMS, ROLE IN SOLID AND HEMATOLOGICAL TUMORS, AND ASSOCIATION WITH VIRAL INFECTIONS

  MAURIZIO MARTINI, Pietro Tralongo, Mariagiovanna Ballato, Vincenzo Fiorentino, Walter Giordano, Valeria zuccalà, Cristina Pizzimenti, Arianna Bakacs, Antonio Ieni, Giovanni Tuccari, Guido Fadda, Luigi Maria Larocca

  e2025052

  2025-06-29

  https://doi.org/10.4084/MJHID.2025.052

  1723

  PDF: 997

  HTML: 188

• Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA

  Michele Puppi, Ilaria Sacchetti, Katia Mancuso, Paola Tacchetti, Lucia Pantani, ilaria Rizzello, Miriam Iezza, Marco Talarico, Enrica Manzato, Simone Masci, Roberta Restuccia, Simona Barbato, Silvia Armuzzi, Barbara Taurisano, Ilaria Vigliotta, Elena Zamagni

  e2025045

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.045

  1607

  PDF: 1229

  HTML: 260

• INFECTIOUS RISKS AND COMPLICATIONS IN ADULT LEUKEMIC PATIENTS RECEIVING BLINATUMOMAB

  Wonhee So, Shuchi Pandya, Rod Quilitz, John Greene

  e2018029

  2018-05-01

  https://doi.org/10.4084/mjhid.2018.029

  2864

  PDF: 1049

  HTML: 304

• SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis

  Roberta Zanotti, Massimiliano Bonifacio, Ilaria Tanasi, Donatella Schena, Giovanni Orsolini, Morena Tebaldi, Lara Crosera, Francesca Mastropaolo, Elisa Olivieri, Dr. Patrizia Bonadonna

  e2021068

  2021-10-29

  https://doi.org/10.4084/MJHID.2021.068

  1545

  PDF: 953

  HTML: 226

• TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi

  e2023038

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.038

  2137

  PDF: 1702

  HTML: 379

• HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH MDS

  Mazyar Shadman, Joachim Deeg

  e2014056

  2014-09-01

  https://doi.org/10.4084/mjhid.2014.056

  2020

  PDF: 760

  HTML: 3113

• CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA CAR T Cells and Myeloma Treatment

  Ugo Testa, Elvira Pelosi, Dr. Germana Castelli

  e2024077

  2024-10-31

  https://doi.org/10.4084/MJHID.2024.077

  1727

  PDF: 844

  HTML: 148

• CMV IN HEMATOPOIETIC STEM CELL TRANSPLANTATION

  Rafael de la Camara

  e2016031

  2016-06-20

  https://doi.org/10.4084/mjhid.2016.031

  4815

  PDF: 1790

  HTML: 2707

  Untitled: 220

• Cauda equina enhancing lesion in a HIV-positive patient. Case report and literature revision.

  Pasquale De Bonis, Antonella Cingolani, Angelo Pompucci, Tommaso Tartaglione, Luigi Maria Larocca, Luciana Teofili

  e2011042

  2011-10-02

  https://doi.org/10.4084/mjhid.2011.042

  1838

  PDF: 845

  HTML: 754

• TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment

  Alessandro Buonomo, Eleonora Nucera, Marianna Criscuolo

  e2022040

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.040

  2101

  PDF: 1528

  HTML: 386

• LUMBAR PUNCTURE: A CROSS-SECTIONAL STUDY USING THE CHINESE VERSION OF THE STATE ANXIETY SCALE FOR CHILDREN.

  Xiuli Qin, Xin Zhao, Ting Zhou, Danyan Yang, Genzhen Yu

  2026-02-28

  https://doi.org/10.4084/MJHID.2026.021

  591

  PDF: 430

  HTML: 79

• Focusing On A Unique Innate Memory Cell Population Of Natural Killer Cells In The Fight Against COVID-19: Harnessing The Ubiquity Of Cytomegalovirus Exposure Memory Cell Population Of Natural Killer Cells in COVID-19 and Cytomegalovirus Exposure

  SUPARNO CHAKRABARTI

  e2020047

  2020-06-28

  https://doi.org/10.4084/mjhid.2020.047

  1178

  PDF: 918

  HTML: 289

• Systemic granulomatous reaction secondary to treatment of bladder cancer with Bacillus Calmette-Guerin

  Caterina Giovanna Valentini, Valentina Bozzoli, Anna Rita Larici, Luigi Maria Larocca, Giovanni Delogu, Giuseppe Leone, Livio Pagano

  e2012040

  2012-06-18

  https://doi.org/10.4084/mjhid.2012.040

  1878

  PDF: 649

  HTML: 19251

• IMMUNITY TO INFECTIONS AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION

  Franco Aversa, Lucia Prezioso, Ilenia Manfra, Federica Galaverna, Angelica Spolzino, Alessandro Monti

  e2016057

  2016-10-25

  https://doi.org/10.4084/mjhid.2016.057

  4346

  PDF: 1113

  HTML: 1426

• IMPACT OF PRETRANSPLANT DONOR AND RECIPIENT CYTOMEGALOVIRUS SEROSTATUS ON OUTCOME FOR MULTIPLE MYELOMA PATIENTS UNDERGOING REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION.

  Jean Elcheikh

  e2013026

  2013-04-10

  https://doi.org/10.4084/mjhid.2013.026

  1296

  PDF: 739

  HTML: 1415

• THE ROLE OF SLC22A4 IN ACUTE MYELOID LEUKEMIA

  Yingying Li, Yang Li, Wenguo Cheng

  e2025073

  2025-10-31

  https://doi.org/10.4084/MJHID.2025.073

  485

  PDF: 248

  HTML: 79

• TOLL-LIKE RECEPTORS IN CHRONIC LYMPHOCYTIC LEUKEMIA

  Marta Muzio, Eleonora Fonte, Federico Caligaris-Cappio

  e2012055

  2012-08-09

  https://doi.org/10.4084/mjhid.2012.055

  2589

  PDF: 867

  HTML: 17565

  Fig1 Caligaris: 172

  Fig.2 Caliga: 205

• The THE PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW: PART 2-FOCUS ON THERAPY

  Michele Bibas

  e2024015

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.015

  1762

  PDF: 1673

  HTML: 867

• BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA BLINATUMOMAB and ALL

  Ugo Testa, Elvira Pelosi, Germana Castelli, Patrizia Chiusolo

  e2024070

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.070

  1641

  PDF: 1097

  HTML: 119

• CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES CAR-T CELL FOR T-CELL MALIGNANCIES

  Ugo Testa, Prof. Patrizia Chiusolo, Dr. Elvira Pelosi, Dr. Germana Castelli, Giuseppe Leone

  e2024031

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.031

  2206

  PDF: 2041

  HTML: 175

• NOVEL DRUGS IN FOLLICULAR LYMPHOMA

  Giuseppe Rossi, Antonella Anastasia

  e2016061

  2016-11-01

  https://doi.org/10.4084/mjhid.2016.061

  4332

  PDF: 1491

  HTML: 1551

  Untitled: 229

• APLASTIC ANEMIA AND VIRAL HEPATITIS

  Laura Cudillo

  e2009026

  https://doi.org/10.4084/mjhid.2009.026

  1260

  PDF: 530

  HTML: 23073

• TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi, Dr. Galli, Prof. Patrizia Chiusolo

  e2025039

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.039

  2220

  PDF: 1503

  HTML: 268

• CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CAR-T CELL and B-ALL

  Ugo Testa, Prof. Sica, Dr. Pelosi, Dr. Germana Castelli, Prof. Leone

  e2024010

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.010

  4199

  PDF: 3471

  HTML: 215

• THE ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE NEW DRUGS ERA.

  Francesco Maura, Lucia Farina, Paolo Corradini

  e2016045

  2016-09-01

  https://doi.org/10.4084/mjhid.2016.045

  4054

  PDF: 1153

  HTML: 1939

  Fig.1: 219

  Fig. 2: 112

  Table 1: 203

  Table2: 220

  Table 3: 199

• Guest Editor: Pellegrino Musto HOW FIRST-LINE THERAPY IS CHANGING IN NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS.

  Daniele Derudas

  e2025025

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.025

  1521

  PDF: 1354

  HTML: 115

• REGULATORY T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA

  Giovanni D'arena, Giovanni Rossi, Barbara Vannata, Silvia Deaglio

  e2012053

  2012-08-09

  https://doi.org/10.4084/mjhid.2012.053

  2331

  PDF: 992

  HTML: 7626

  Untitled: 277

  Fig2: 184

  Fig3: 169

  Fig4: 181

• Is laboratory monitoring useful in DOACs management?

  Mario Biglietto, Rosaria Mormile, Matteo Totaro, Maria Laura Bisegna, Cristina Santoro, Antonio Chistolini

  e2025019

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.019

  839

  PDF: 808

  HTML: 108

• Guest Editor: Pellegrino Musto AN UPDATE OF THE APPROPRIATE SEQUENCING FOR SALVAGE THERAPIES IN MULTIPLE MYELOMA

  Gregorio Barila', Francesca Rezzonico, Laura Pavan, Alessandro Corso, Renato Zambello

  e2025043

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.043

  1176

  PDF: 960

  HTML: 148

• REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY Real-world Assessment of Myeloma Patients as Candidates for CAR-T Therapy

  Ulrike Bacher, Simon Brechbühl, Barbara Jeker, Thomas Pabst

  e2021012

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.012

  1586

  PDF: 610

  HTML: 192

• Sarcoid-like Reactions in Hodgkin Lymphoma Treated with Pembrolizumab: a Case Report

  Pier Luigi Zinzani, Flavia Salvatore, Beatrice Casadei, Camilla Mazzoni, Marianna Gentilini, Giulia Gabrielli, Lisa Argnani

  e2026052

  2026-06-30

  https://doi.org/10.4084/MJHID.2026.052

  85

  PDF: 9

  HTML: 6

• Hemophagocytic lymphohistiocytosis: an unusual complication in Orientia tsutsugamushi disease (scrub typhus).

  Aneesh Basheer, Somanath Padhi, Vinoth Boopathy, Saumyaranjan Mallick, Shashikala Nair, Renu G'Boy Varghese, Reba Kanungo

  e2015008

  2014-12-23

  https://doi.org/10.4084/mjhid.2015.008

  4038

  PDF: 1546

  HTML: 4364

• MOLECULAR MECHANISM OF TRAF6 IN MALIGNANT PROLIFERATION OF HUMAN NK/T CELL LYMPHOMA CELL HANK1

  Yan Qi, Chengbo Xu, Zesong Chen, Jiawei Chen, Congjie Chen

  e2025074

  2025-10-31

  https://doi.org/10.4084/MJHID.2025.074

  516

  PDF: 278

  html: 39

• CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS CAR-T and Follicular Lymphoma

  Ugo Testa, Francesco D'Alò, Elvira Pelosi, Germana Castelli, Giuseppe Leone

  e2024012

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.012

  2296

  PDF: 1832

  HTML: 144

• ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN THE TREATMENT OF CHRONIC LYMPHOCITIC LEUKEMIA : WHY AND WHEN ?

  Maria L. Delioukina, Stephen J. Forman

  e2010018

  2010-06-30

  https://doi.org/10.4084/mjhid.2010.018

  1243

  PDF: 791

  HTML: 542

• ROLE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION

  Angelo Michele Carella

  e2012059

  2012-10-02

  https://doi.org/10.4084/mjhid.2012.059

  2033

  PDF: 803

  HTML: 1045

• OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANT BEFORE AVAILABILITY OF CAR-T CELL TREATMENT Outcome of DLBCL patients relapsing after ASCT

  Ulrike Bacher, Stefanie von Matt, Yara Banz, Behrouz Mansouri, Urban Novak, Thomas Pabst

  e2023025

  2023-04-28

  https://doi.org/10.4084/MJHID.2023.025

  1315

  HTML: 308

  PDF: 941

  Suppl. Files: 459

• PLASMACELL NEOPLASMS WITH SPREADING IN THE BLOOD AND TISSUES: EXTRAMEDULLARY MYELOMA DISEASE A RARE AGGRESSIVE FORM OF MULTIPLE MYELOMA (First of two parts) Extra Medullary Myeloma

  Ugo Testa; Giuseppe G.M. Leone

  e2025005

  2024-12-31

  https://doi.org/10.4084/MJHID.2025.005

  2466

  HTML: 274

  PDF: 876

• "ROLE OF ALLOGENEIC TRANSPLANTATION IN MULTIPLE MYELOMA IN THE ERA OF NEW DRUGS"

  Benedetto Bruno, Luisa Giaccone, Moreno Festuccia, Mario Boccadoro

  e2010013

  2010-06-01

  https://doi.org/10.4084/mjhid.2010.013

  1416

  PDF: 663

  HTML: 1507

• COVID-19 IN CHILDREN AND ADOLESCENT: CHARACTERISTICS AND SPECIFICITIES IN IMMUNOCOMPETENT AND ONCOHEMATOLOGICAL PATIENTS COVID-19 IN CHILDREN AND ADOLESCENT.

  Federico Mercolini, Simone Cesaro

  e2022009

  2022-01-01

  https://doi.org/10.4084/MJHID.2022.009

  2411

  PDF: 939

  HTML: 303

• IMMUNOLOGICAL DEREGULATION IN HODGKIN’S DISEASE

  Francesco Di Raimondo, Giorgio La Nasa

  e2014039

  2014-05-29

  https://doi.org/10.4084/mjhid.2014.039

  2227

  PDF: 966

  HTML: 1899

• Achieving the cure of follicular lymphoma: is it time to finalize treatment strategies to reach this goal in a subset of patients?

  Mauro Passucci, Giovanni Assanto, Alessandro Pulsoni

  e2023018

  2023-02-28

  https://doi.org/10.4084/MJHID.2023.018

  1192

  PDF: 912

  HTML: 359

• EPSTEIN-BARR VIRUS RELATED LYMPHOPROLIFERATIONS AFTER STEM CELL TRANSPLANTATION

  Simona Sica, Elisabetta Metafuni, Silvia Bellesi, Patrizia Chiusolo

  e2009019

  2009-12-14

  https://doi.org/10.4084/mjhid.2009.019

  1339

  PDF: 567

  HTML: 2988

• THE USE OF MONOCLONAL ANTIBODIES IN THE TREATMENT OF AUTOIMMUNE COMPLICATIONS OF CHRONIC LYMPHOCYTIC LEUKEMIA

  Luca Laurenti

  e2013027

  2013-04-10

  https://doi.org/10.4084/mjhid.2013.027

  2176

  PDF: 1036

  HTML: 2718

• TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS

  Eleonora De Bellis, Luana Fianchi, Francesco Buccisano, Marianna Criscuolo, Luca Maurillo, Laura Cicconi, Mattia Brescini, Maria Ilaria Del Principe, Ambra Di Veroli, Adriano Venditti, Francesco Lo-Coco, Maria Teresa Voso

  e2017045

  2017-07-01

  https://doi.org/10.4084/mjhid.2017.045

  4331

  PDF: 1765

  HTML: 1107

• FROM LEGACY TO INNOVATION: PIDOTIMOD’S EXPANDING THERAPEUTIC HORIZON Pidotimod: Revisiting a Classic Immunomodulator

  Claudio Ucciferri, Francesca Chiappini, Jacopo Vecchiet, Katia Falasca

  e2025057

  2025-08-31

  https://doi.org/10.4084/MJHID.2025.057

  2485

  PDF: 935

  HTML: 555

• CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi

  e2022069

  2022-08-27

  https://doi.org/10.4084/MJHID.2022.069

  2977

  PDF: 903

  HTML: 1969

• COMPARISON OF THREE DISTINCT PROPHYLACTIC AGENTS AGAINST INVASIVE FUNGAL INFECTIONS IN PATIENTS UNDERGOING HAPLO-IDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION AND POST-TRANSPLANT CYCLOPHOSPHAMIDE

  Jean Elcheikh

  e2015048

  2015-08-21

  https://doi.org/10.4084/mjhid.2015.048

  1899

  PDF: 1014

  HTML: 1348